Research and Markets (http://www.researchandmarkets.com/research/8e2ae7/romania_pharmaceut)
has announced the addition of the "Romania
Pharmaceuticals and Healthcare Report Q1 2010" report to their
offering.
“Romania
Pharmaceuticals and Healthcare Report Q1 2010”
The Romania Pharmaceuticals and Healthcare Report provides industry
professionals and strategists, corporate analysts, pharmaceutical
associations, government departments and regulatory bodies with
independent forecasts and competitive intelligence on Romania's
pharmaceuticals and healthcare industry.
In the Business Environment Rating matrix for Q110, we see Romania move
down one place to occupy fifth position out of the 15 regional markets
surveyed among the emerging economies of Europe. Despite its marginal
drop in the table, Romania's current position reflects the robust nature
of the country's pharmaceutical industry and the strong growth it has
seen in recent months. We therefore envisage that sales of
pharmaceutical products will increase over the next 10 years, with sales
of prescription drugs and over-the-counter (OTC) medicines expected to
grow from US$3.31bn in 2008 to US$8.24bn by 2019, representing local
currency compound annual growth rates (CAGRs) of 10.10% and 7.34% for
2009-14 and 2014-19, respectively.
Latest figures suggest that pharmaceutical sales in Romania continued to
show strong growth in 2009. Data released by market research firm IMS
Health identified a 19.9% year-on-year (y-o-y) rise in medicine sales in
local currency terms, reaching RON6.3bn (US$2.2bn) for Q309, although
growth in the sales of OTC medications experienced a strong dampening
effect as a result of declining consumer incomes. Prescription medicines
however, continued to grow, seemingly unabated by economic pressures.